SCHEMBL20127047

SCHEMBL20127047

Cc1nccn1-c1cc(C(=O)NC(C)(C)C)cc(-c2ccc(C(F)(F)F)cc2)n1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.44
ALDH1A1 P00352 3/20 0.44
P2RY14 Q15391 2/20 0.43
ADORA3 P0DMS8 1/20 0.42
HPGD P15428 2/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
RAF1 P04049 1/20 0.41
BRAF P15056 1/20 0.41
MCHR1 Q99705 2/20 0.41
RIPK1 Q13546 1/20 0.39
ALOX5AP P20292 2/20 0.39
FEN1 P39748 2/20 0.39
POLB P06746 1/20 0.39
HDAC1 Q13547 2/20 0.39
KDM1A O60341 1/20 0.38
TRPV1 Q8NER1 1/20 0.38
CSF1R P07333 1/20 0.38
LYN P07948 1/20 0.38
KIT P10721 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18389611 0.90 NAMPT (0.40) KDM4EALDH1A1ADORA3HPGDMEN1
SCHEMBL18389394 0.89 TUBB4A (0.41) KDM4EALDH1A1ADORA3HPGDMEN1
SCHEMBL18389397 0.89 P2RY14 (0.42) KDM4EALDH1A1P2RY14ADORA3HPGD
SCHEMBL18389428 0.88 P2RY14 (0.42) KDM4EALDH1A1P2RY14ADORA3HPGD
SCHEMBL18389336 0.88 CNR1 (0.44) KDM4EALDH1A1ADORA3HPGDMEN1
SCHEMBL18389516 0.87 P2RY14 (0.41) KDM4EALDH1A1P2RY14ADORA3HPGD
SCHEMBL20127042 0.85 MCHR1 (0.41) P2RY14ADORA3MCHR1
SCHEMBL18389378 0.80 ADORA3 (0.50) KDM4EALDH1A1P2RY14ADORA3HPGD
SCHEMBL20127046 0.79 RIPK1 (0.38) ALDH1A1ADORA3RIPK1HDAC1KDM1A
SCHEMBL18389327 0.78 MAPT (0.39) ALDH1A1ADORA3RIPK1ALOX5APFEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107709311-B 2-phenyl-6-imidazolyl-pyridine-4-carboxamide derivatives and their use as EAAT3 inhibitors 豪夫迈·罗氏有限公司 2020-09-25 CN claimed
EP-3322699-B1 2-PHENYL-6-IMIDAZOLYL-PYRIDINE-4-CARBOXAMIDE DERIVATIVES AND THEIR USE AS EAAT3 INHIBITORS HOFFMANN LA ROCHE (CH) 2019-05-15 EP claimed
CN-107709311-B 2-phenyl-6-imidazolyl-pyridine-4-carboxamide derivatives and their use as EAAT3 inhibitors 豪夫迈·罗氏有限公司 2020-09-25 CN disclosed
EP-3322699-B1 2-PHENYL-6-IMIDAZOLYL-PYRIDINE-4-CARBOXAMIDE DERIVATIVES AND THEIR USE AS EAAT3 INHIBITORS HOFFMANN LA ROCHE (CH) 2019-05-15 EP disclosed
US-20180125823-A1 IMIDAZOLE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2018-05-10 US disclosed
US-20180125823-A1 IMIDAZOLE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2018-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180125823-A1 IMIDAZOLE DERIVATIVES OXTR, DRD3, MC3R KDM4E 2622/4885ALDH1A1 770/4885P2RY14 3542/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.